• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name:  ibritumomab tiuxetan
Trade Name:  Zevalin
Date Designated:  09/06/1994
Orphan Designation:  Treatment of B-cell non-Hodgkin's lymphoma.
Orphan Designation Status:  Designated/Approved
Marketing Approval Date:  02/19/2002 
Approved Labeled Indication:  Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma
Exclusivity End Date:    02/19/2009 
Exclusivity Protected Indication* :  
Acrotech Biopharma LLC
279 Princeton Hightstown Road
East Windsor, New Jersey 08520
United States

The sponsor address listed is the last reported by the sponsor to OOPD.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.